Korro Bio (KRRO) Assets Average (2019 - 2026)
Korro Bio's (KRRO) quarterly Assets Average came in at $173.5 million in Q2 2026, down 9.29% on a YoY basis from $191.3 million in Q2 2025, and up 16.81% quarter-over-quarter from $148.6 million in Q1 2026.
Analysis
Korro Bio (KRRO) Assets Average (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has reported Assets Average for 8 consecutive years, with $173.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average fell 9.29% year-over-year to $173.5 million; the trailing twelve-month figure through Jun 2026 stood at $173.5 million (down 9.29% YoY), and the FY2025 full-year result was $169.9 million, down 24.15% from the prior year.
- Assets Average grew to $173.5 million in Q2 2026 per KRRO's latest filing, from $148.6 million in the prior quarter.
- Across five years, Assets Average topped out at $246.6 million in Q3 2024 and bottomed at $62.9 million in Q3 2023.
- Historically, Assets Average has averaged $161.5 million across 5 years, with a median of $164.1 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Assets Average slumped 55.99% in 2023, then jumped 292.21% in 2024.
- Over 5 years, Assets Average stood at $104.9 million in 2022, then rose by 27.77% to $134.0 million in 2023, then soared by 75.28% to $234.9 million in 2024, then slumped by 41.45% to $137.5 million in 2025, then rose by 26.18% to $173.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $173.5 million, $148.6 million, and $137.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Korro Bio | 227.98 Mn | 112.95 Mn | - | 173.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 173.53 Mn |
| Mar 31, 2026 | 148.56 Mn |
| Dec 31, 2025 | 137.53 Mn |
| Sep 30, 2025 | 170.99 Mn |
| Jun 30, 2025 | 191.32 Mn |
| Mar 31, 2025 | 214.22 Mn |
| Dec 31, 2024 | 234.89 Mn |
| Sep 30, 2024 | 246.57 Mn |
| Jun 30, 2024 | 223.79 Mn |
| Mar 31, 2024 | 209.82 Mn |
| Dec 31, 2023 | 134.01 Mn |
| Sep 30, 2023 | 62.87 Mn |
| Jun 30, 2023 | 90.44 Mn |
| Mar 31, 2023 | 87.62 Mn |
| Dec 31, 2022 | 104.88 Mn |
| Sep 30, 2022 | 142.84 Mn |
| Jun 30, 2022 | 157.30 Mn |
| Mar 31, 2022 | 175.15 Mn |
| Dec 31, 2021 | 193.77 Mn |
| Sep 30, 2021 | 211.20 Mn |